Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Risperidone versus typical antipsychotic medication for schizophrenia.

E Kennedy1, F Song, R Hunter

  • 1Research and Development Directorate, Gartnavel Royal Hospital, 1055 Great Western Road, Glasgow, UK, G12 0XH. jcahoon@udcf.gla.ac.uk

The Cochrane Database of Systematic Reviews
|May 5, 2000
PubMed
Summary

Risperidone, a new generation antipsychotic, shows moderate clinical improvement in schizophrenia patients compared to conventional drugs. It is more acceptable and causes fewer movement disorders but may lead to weight gain.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The governance of surgical innovation in the UK National Health Service.

The British journal of surgery·2026
Same author

The effects of simultaneous isometric and eccentric- or concentric-biased exercise on cardiovascular and muscular health of young individuals.

European journal of applied physiology·2026
Same author

The distribution of healthcare workforces relative to population ill health in England: Repeated cross-sectional analysis of Census data 2001-2021.

Public health·2025
Same author

Prevalence of transthyretin cardiac amyloidosis in undifferentiated heart failure with preserved ejection fraction.

ESC heart failure·2024
Same author

The inflexible mind: A critical factor in understanding and addressing COVID-19 vaccine hesitancy.

Journal of psychiatric research·2024
Same author

An outbreak of SARS-CoV-2 in a public-facing office in England.

Occupational medicine (Oxford, England)·2023

Area of Science:

  • Psychiatry and Pharmacology
  • Clinical Trials and Evidence-Based Medicine

Background:

  • Conventional antipsychotics (e.g., haloperidol) are first-line for schizophrenia but have limited efficacy for negative symptoms and problematic side effects.
  • New generation antipsychotics like risperidone are explored for improved efficacy and tolerability, particularly for negative symptoms and movement disorders.

Purpose of the Study:

  • To evaluate the effectiveness of risperidone against conventional neuroleptic drugs in schizophrenia treatment.
  • To compare clinical improvement, side effects (movement disorders), and treatment acceptability.

Main Methods:

  • Systematic review of randomized trials comparing risperidone to conventional neuroleptics for schizophrenia.
  • Electronic database searches (1980-1997) and contact with pharmaceutical companies and trial authors.

Related Experiment Videos

  • Data extraction and analysis included odds ratios, confidence intervals, and number needed to treat for primary outcomes.

    • Main Results:

    • Risperidone demonstrated moderate clinical improvement (NNT 10) and was more acceptable (NNT 15) than conventional treatments.
    • Significantly fewer movement disorders (NNT 7) were observed with risperidone compared to haloperidol.
    • Risperidone was associated with increased somnolence (NNT 22) and weight gain (NNT 13); no significant effect on positive/negative symptoms was found.

    Conclusions:

    • Risperidone may offer improved acceptability and marginal clinical benefits over conventional antipsychotics, with fewer movement disorders.
    • Limited data exist on long-term effects, cognitive function, quality of life, or relapse rates.
    • Generalizing findings beyond comparisons with haloperidol is cautioned due to potential publication bias and study limitations.